Dianthus Therapeutics Quarterly Income Statement
NASDAQ: DNTHHealth CareBiotechnology: Pharmaceutical PreparationsUSD
82.37-0.06 (-0.07%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Dianthus Therapeutics revenue and earnings
Dianthus Therapeutics reported a net loss of $50.2 million, compared with a loss of $31.6 million a year earlier. Diluted earnings per share came in at -$0.90.
Summary generated from market data by MetaCap's automated system. Methodology
Dianthus Therapeutics income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | 284.00K | 396.00K | 193.00K | 1.16M | 1.33M | 2.17M | 1.86M | 874.00K | 457.00K | 924.00K |
| Revenue growth (YoY) | — | — | -78.58% | -81.77% | -89.64% | +33.07% | +190.15% | +135.06% | — | — | — | -21.23% |
| Operating Expenses | 62.24M | 47.00M | 69.83M | 40.68M | 35.12M | 34.34M | 33.24M | 32.07M | 24.07M | 18.72M | 13.41M | 16.68M |
| Research & Development | 48.69M | 34.53M | 59.90M | 32.49M | 26.25M | 27.00M | 26.41M | 25.54M | 18.07M | 13.08M | 8.78M | 7.96M |
| Operating Income | -61.48M | -46.53M | -69.54M | -40.29M | -34.93M | -33.18M | -31.92M | -29.90M | -22.20M | -17.84M | -12.96M | -15.76M |
| Other Income (Expense) | 11.27M | 5.70M | 5.11M | 3.52M | 3.30M | 3.67M | 3.48M | 4.73M | 4.60M | 4.10M | 2.39M | 996.00K |
| Net Income | -50.22M | -40.83M | -64.43M | -36.77M | -31.63M | -29.51M | -28.44M | -25.17M | -17.61M | -13.75M | -10.56M | -14.76M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -0.90 | -0.85 | -1.53 | -0.97 | -0.88 | -0.82 | -0.76 | -0.74 | -0.51 | -0.54 | 16.16 | -3.78 |
| EPS (Diluted) | -0.90 | -0.85 | -1.53 | -0.97 | -0.88 | -0.82 | -0.76 | -0.74 | -0.51 | -0.54 | 16.16 | -3.78 |
| Shares Outstanding (Basic) | 56.03M | 48.03M | — | 37.79M | 35.82M | 35.79M | — | 34.24M | 34.23M | 25.67M | — | 3.91M |
| Shares Outstanding (Diluted) | 56.03M | 48.03M | — | 37.79M | 35.82M | 35.79M | — | 34.24M | 34.23M | 25.67M | — | 3.91M |
| EBITDA | -61.45M | -46.50M | -69.51M | -40.26M | -34.90M | -33.15M | -31.89M | -29.88M | -22.18M | -17.82M | -12.94M | -15.74M |
| Operating Margin | — | — | -24486.27% | -10173.74% | -18096.89% | -2852.71% | -2406.94% | -1376.61% | -1191.84% | -2041.65% | -2835.01% | -1705.52% |
| Net Margin | — | — | -22687.32% | -9284.09% | -16388.08% | -2537.49% | -2144.80% | -1159.02% | -945.09% | -1573.00% | -2311.38% | -1597.73% |
This table shows 12 quarterly periods of Dianthus Therapeutics's income statement, from Q2 2026 back to Q3 2023, across 14 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow DNTH's reporting calendar. What is a income statement?